| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infertility, Female | 22 | 2004 | 98 | 1.200 |
Why?
|
| Endometriosis | 22 | 2001 | 63 | 1.090 |
Why?
|
| Tissue Adhesions | 11 | 2000 | 53 | 0.810 |
Why?
|
| Uterus | 7 | 2003 | 225 | 0.770 |
Why?
|
| Polytetrafluoroethylene | 6 | 1997 | 72 | 0.630 |
Why?
|
| Uterine Neoplasms | 6 | 2003 | 277 | 0.500 |
Why?
|
| Hysterectomy | 4 | 2007 | 167 | 0.440 |
Why?
|
| Leiomyoma | 4 | 2003 | 211 | 0.440 |
Why?
|
| Endometrium | 6 | 2004 | 51 | 0.420 |
Why?
|
| Ascitic Fluid | 12 | 2002 | 36 | 0.390 |
Why?
|
| Menotropins | 8 | 1991 | 20 | 0.370 |
Why?
|
| Insemination, Artificial | 7 | 1993 | 15 | 0.360 |
Why?
|
| Postoperative Complications | 9 | 2000 | 2552 | 0.350 |
Why?
|
| Peritoneum | 3 | 2000 | 52 | 0.350 |
Why?
|
| Ovulation Induction | 6 | 1997 | 29 | 0.350 |
Why?
|
| Embolization, Therapeutic | 3 | 2003 | 272 | 0.340 |
Why?
|
| Infertility | 6 | 1997 | 34 | 0.340 |
Why?
|
| Superovulation | 5 | 1993 | 9 | 0.340 |
Why?
|
| Ovariectomy | 3 | 2007 | 91 | 0.320 |
Why?
|
| Peritoneal Cavity | 6 | 1996 | 19 | 0.320 |
Why?
|
| Cellulose | 3 | 1996 | 59 | 0.320 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2007 | 48 | 0.310 |
Why?
|
| Luteinizing Hormone | 7 | 1997 | 144 | 0.300 |
Why?
|
| Ovary | 6 | 2002 | 252 | 0.290 |
Why?
|
| Macrophages | 12 | 1994 | 609 | 0.290 |
Why?
|
| Progesterone | 7 | 1993 | 114 | 0.290 |
Why?
|
| Female | 73 | 2007 | 48542 | 0.270 |
Why?
|
| Hormones | 5 | 1993 | 136 | 0.250 |
Why?
|
| Estradiol | 8 | 2006 | 247 | 0.240 |
Why?
|
| Macrophages, Peritoneal | 3 | 2002 | 25 | 0.230 |
Why?
|
| Sperm Motility | 4 | 1995 | 10 | 0.230 |
Why?
|
| Pregnancy | 15 | 2003 | 3128 | 0.220 |
Why?
|
| Gonadotropin-Releasing Hormone | 5 | 2000 | 100 | 0.220 |
Why?
|
| Prostheses and Implants | 2 | 1997 | 121 | 0.220 |
Why?
|
| Reproductive Medicine | 1 | 2004 | 7 | 0.220 |
Why?
|
| Ovulation | 6 | 1994 | 65 | 0.200 |
Why?
|
| Chorionic Gonadotropin | 6 | 1997 | 69 | 0.200 |
Why?
|
| Abortion, Habitual | 1 | 2003 | 31 | 0.200 |
Why?
|
| Peritoneal Diseases | 2 | 1994 | 15 | 0.200 |
Why?
|
| Fertilization in Vitro | 6 | 1991 | 53 | 0.190 |
Why?
|
| Cellulose, Oxidized | 2 | 1992 | 4 | 0.180 |
Why?
|
| Granulosa Cells | 4 | 1990 | 31 | 0.170 |
Why?
|
| Peritonitis | 2 | 1994 | 28 | 0.170 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2000 | 35 | 0.160 |
Why?
|
| Medroxyprogesterone | 2 | 1991 | 6 | 0.160 |
Why?
|
| Uterine Diseases | 3 | 1997 | 19 | 0.160 |
Why?
|
| Humans | 66 | 2007 | 93132 | 0.160 |
Why?
|
| Fallopian Tubes | 4 | 2003 | 48 | 0.150 |
Why?
|
| Wound Healing | 2 | 2000 | 372 | 0.150 |
Why?
|
| Leuprolide | 5 | 1993 | 34 | 0.150 |
Why?
|
| Adult | 30 | 2006 | 27849 | 0.150 |
Why?
|
| Laparoscopy | 4 | 2003 | 765 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2000 | 185 | 0.140 |
Why?
|
| Bandages | 1 | 1998 | 42 | 0.140 |
Why?
|
| Hyaluronic Acid | 1 | 1998 | 46 | 0.140 |
Why?
|
| Estrogens | 6 | 2007 | 194 | 0.140 |
Why?
|
| Fertilization | 2 | 1994 | 42 | 0.130 |
Why?
|
| Ovulation Detection | 1 | 1997 | 5 | 0.130 |
Why?
|
| Galactorrhea | 1 | 1997 | 6 | 0.130 |
Why?
|
| Coitus | 2 | 1994 | 19 | 0.130 |
Why?
|
| Hot Flashes | 2 | 2007 | 12 | 0.130 |
Why?
|
| Patient Selection | 1 | 2000 | 688 | 0.120 |
Why?
|
| Interleukin-1 | 2 | 1995 | 71 | 0.120 |
Why?
|
| Receptors, Progesterone | 3 | 1991 | 195 | 0.110 |
Why?
|
| Fertility | 2 | 1997 | 119 | 0.110 |
Why?
|
| Menstrual Cycle | 7 | 1991 | 65 | 0.110 |
Why?
|
| Pelvic Neoplasms | 2 | 1993 | 42 | 0.110 |
Why?
|
| Peritoneal Neoplasms | 2 | 1988 | 183 | 0.110 |
Why?
|
| Mice | 11 | 2002 | 12230 | 0.110 |
Why?
|
| Receptors, Estrogen | 3 | 1991 | 412 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 1995 | 688 | 0.110 |
Why?
|
| Spermatozoa | 4 | 1987 | 68 | 0.100 |
Why?
|
| Pregnancy, Animal | 1 | 1994 | 58 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 1995 | 281 | 0.100 |
Why?
|
| Embryo Transfer | 3 | 1987 | 26 | 0.100 |
Why?
|
| Hysteroscopy | 2 | 2003 | 6 | 0.090 |
Why?
|
| Membranes, Artificial | 1 | 1992 | 38 | 0.090 |
Why?
|
| Interferon-gamma | 2 | 2002 | 459 | 0.090 |
Why?
|
| Arteries | 2 | 2003 | 170 | 0.090 |
Why?
|
| Animals | 14 | 2002 | 27973 | 0.090 |
Why?
|
| Cautery | 1 | 1991 | 2 | 0.080 |
Why?
|
| Diethylstilbestrol | 2 | 1983 | 119 | 0.080 |
Why?
|
| Insemination, Artificial, Homologous | 2 | 1987 | 3 | 0.080 |
Why?
|
| Condylomata Acuminata | 1 | 1990 | 11 | 0.080 |
Why?
|
| Estradiol Congeners | 1 | 1990 | 8 | 0.080 |
Why?
|
| Oocytes | 2 | 1987 | 211 | 0.080 |
Why?
|
| Ovarian Cysts | 1 | 1989 | 15 | 0.080 |
Why?
|
| Vagina | 2 | 1995 | 177 | 0.080 |
Why?
|
| Vaginal Neoplasms | 1 | 1990 | 84 | 0.080 |
Why?
|
| Oxidation-Reduction | 3 | 1996 | 410 | 0.080 |
Why?
|
| Menopause | 3 | 2007 | 87 | 0.070 |
Why?
|
| Progestins | 2 | 2007 | 22 | 0.070 |
Why?
|
| Clomiphene | 3 | 1990 | 17 | 0.070 |
Why?
|
| Sperm-Ovum Interactions | 1 | 1989 | 1 | 0.070 |
Why?
|
| Cervix Uteri | 1 | 1989 | 73 | 0.070 |
Why?
|
| Pregnancy, Multiple | 1 | 1988 | 37 | 0.070 |
Why?
|
| Aging | 2 | 1990 | 725 | 0.070 |
Why?
|
| Ovarian Neoplasms | 3 | 2003 | 795 | 0.070 |
Why?
|
| Ovarian Diseases | 1 | 1987 | 28 | 0.070 |
Why?
|
| Vaginal Diseases | 1 | 2007 | 27 | 0.060 |
Why?
|
| Prolactin | 2 | 1984 | 89 | 0.060 |
Why?
|
| Hysterosalpingography | 2 | 2003 | 7 | 0.060 |
Why?
|
| Electrocoagulation | 2 | 1998 | 22 | 0.060 |
Why?
|
| Acetaminophen | 1 | 1987 | 61 | 0.060 |
Why?
|
| Female Urogenital Diseases | 1 | 2006 | 8 | 0.060 |
Why?
|
| Reproduction | 2 | 1994 | 205 | 0.060 |
Why?
|
| Male | 15 | 1997 | 44355 | 0.060 |
Why?
|
| Body Fluids | 1 | 1984 | 35 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1987 | 249 | 0.050 |
Why?
|
| Drug Therapy, Combination | 4 | 1991 | 753 | 0.050 |
Why?
|
| Sperm Count | 2 | 1997 | 9 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 1998 | 710 | 0.050 |
Why?
|
| Pregnancy Trimester, First | 1 | 2003 | 63 | 0.050 |
Why?
|
| Reoperation | 2 | 1997 | 696 | 0.050 |
Why?
|
| Congenital Abnormalities | 1 | 2003 | 64 | 0.050 |
Why?
|
| Exudates and Transudates | 2 | 1993 | 13 | 0.050 |
Why?
|
| Mice, Inbred C3H | 2 | 1994 | 368 | 0.050 |
Why?
|
| Microspheres | 1 | 2002 | 88 | 0.050 |
Why?
|
| Sterilization Reversal | 1 | 1982 | 2 | 0.050 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2002 | 23 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 1993 | 279 | 0.050 |
Why?
|
| Teratoma | 1 | 2003 | 55 | 0.050 |
Why?
|
| Cell Count | 3 | 1991 | 195 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2000 | 2479 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1983 | 175 | 0.040 |
Why?
|
| Intestinal Obstruction | 1 | 2003 | 93 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2003 | 171 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 123 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2007 | 9070 | 0.040 |
Why?
|
| Biopsy | 1 | 2004 | 1172 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 1991 | 2301 | 0.040 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2000 | 10 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2003 | 10128 | 0.040 |
Why?
|
| Pregnancy Outcome | 2 | 1993 | 267 | 0.040 |
Why?
|
| Risk Factors | 2 | 2007 | 5900 | 0.040 |
Why?
|
| Endocrine Glands | 1 | 1980 | 13 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2000 | 87 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 429 | 0.040 |
Why?
|
| Forecasting | 1 | 2000 | 288 | 0.040 |
Why?
|
| Clinical Trials as Topic | 4 | 1996 | 1098 | 0.040 |
Why?
|
| Reference Values | 3 | 2002 | 603 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2000 | 167 | 0.040 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1979 | 20 | 0.040 |
Why?
|
| Anesthesia, General | 1 | 1980 | 127 | 0.040 |
Why?
|
| Regression Analysis | 2 | 1991 | 573 | 0.040 |
Why?
|
| Anesthesia, Intravenous | 1 | 1998 | 36 | 0.030 |
Why?
|
| Cryopreservation | 2 | 1990 | 70 | 0.030 |
Why?
|
| Time Factors | 3 | 1994 | 5380 | 0.030 |
Why?
|
| Phagocytosis | 4 | 1987 | 111 | 0.030 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 1990 | 193 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 3 | 1995 | 129 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1980 | 217 | 0.030 |
Why?
|
| Recurrence | 1 | 2000 | 1188 | 0.030 |
Why?
|
| Bromocriptine | 1 | 1997 | 12 | 0.030 |
Why?
|
| Hormone Antagonists | 1 | 1997 | 18 | 0.030 |
Why?
|
| Pelvic Inflammatory Disease | 2 | 1987 | 9 | 0.030 |
Why?
|
| Swine | 2 | 1990 | 585 | 0.030 |
Why?
|
| Cells, Cultured | 5 | 2002 | 2827 | 0.030 |
Why?
|
| Disease Progression | 1 | 2000 | 1529 | 0.030 |
Why?
|
| Middle Aged | 8 | 2006 | 27535 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 1171 | 0.030 |
Why?
|
| Molsidomine | 1 | 1995 | 6 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1995 | 25 | 0.030 |
Why?
|
| Indomethacin | 1 | 1995 | 58 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 1995 | 62 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 1995 | 294 | 0.030 |
Why?
|
| Uterine Hemorrhage | 2 | 1988 | 21 | 0.030 |
Why?
|
| Macrophage Activation | 2 | 2002 | 52 | 0.030 |
Why?
|
| Hemoglobins | 1 | 1995 | 188 | 0.030 |
Why?
|
| Adolescent | 3 | 1995 | 9550 | 0.030 |
Why?
|
| Menstruation Disturbances | 2 | 1988 | 22 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 1995 | 700 | 0.030 |
Why?
|
| Fallopian Tube Diseases | 2 | 1984 | 4 | 0.030 |
Why?
|
| Embryo Implantation | 1 | 1994 | 24 | 0.030 |
Why?
|
| Adnexa Uteri | 1 | 1994 | 11 | 0.030 |
Why?
|
| Mice, Inbred ICR | 1 | 1994 | 75 | 0.030 |
Why?
|
| Abdominal Muscles | 1 | 1994 | 23 | 0.030 |
Why?
|
| Body Temperature | 1 | 1994 | 127 | 0.030 |
Why?
|
| Hydrogen Peroxide | 2 | 1992 | 164 | 0.030 |
Why?
|
| Causality | 1 | 1993 | 82 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 166 | 0.020 |
Why?
|
| Cell Communication | 1 | 1994 | 217 | 0.020 |
Why?
|
| Leukocytes | 1 | 1994 | 210 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 1909 | 0.020 |
Why?
|
| Androgens | 2 | 1987 | 163 | 0.020 |
Why?
|
| Growth Substances | 1 | 1993 | 79 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 2562 | 0.020 |
Why?
|
| Monocytes | 2 | 1991 | 214 | 0.020 |
Why?
|
| Antibodies | 2 | 1985 | 346 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 1995 | 502 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1992 | 125 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 1991 | 63 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1991 | 23 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1991 | 18 | 0.020 |
Why?
|
| Fibrosis | 1 | 1993 | 228 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 2465 | 0.020 |
Why?
|
| Gamete Intrafallopian Transfer | 1 | 1991 | 3 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1988 | 209 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 1994 | 343 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 1991 | 38 | 0.020 |
Why?
|
| Postmenopause | 2 | 2006 | 106 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 2705 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 944 | 0.020 |
Why?
|
| Prospective Studies | 2 | 1997 | 4546 | 0.020 |
Why?
|
| Luteal Phase | 1 | 1990 | 14 | 0.020 |
Why?
|
| Ovarian Follicle | 1 | 1990 | 65 | 0.020 |
Why?
|
| HIV-1 | 1 | 1991 | 173 | 0.020 |
Why?
|
| Teratogens | 1 | 1990 | 11 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 1990 | 49 | 0.020 |
Why?
|
| Metaplasia | 1 | 1990 | 40 | 0.020 |
Why?
|
| Menstruation | 1 | 1990 | 35 | 0.020 |
Why?
|
| Mullerian Ducts | 1 | 1990 | 20 | 0.020 |
Why?
|
| Incidence | 1 | 1994 | 1697 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 1990 | 179 | 0.020 |
Why?
|
| Phagocytes | 1 | 1988 | 15 | 0.020 |
Why?
|
| Cytokines | 1 | 1993 | 862 | 0.020 |
Why?
|
| Biological Assay | 1 | 1989 | 82 | 0.020 |
Why?
|
| alpha-Macroglobulins | 1 | 1988 | 3 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 1989 | 82 | 0.020 |
Why?
|
| Anovulation | 2 | 1989 | 10 | 0.020 |
Why?
|
| Trypsin | 1 | 1988 | 90 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1988 | 241 | 0.020 |
Why?
|
| Cattle | 1 | 1989 | 392 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 1987 | 9 | 0.020 |
Why?
|
| Sperm Transport | 1 | 1987 | 1 | 0.020 |
Why?
|
| Cervix Mucus | 1 | 1987 | 4 | 0.020 |
Why?
|
| Muramidase | 1 | 1987 | 32 | 0.020 |
Why?
|
| Professional Misconduct | 1 | 1987 | 20 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1991 | 1786 | 0.020 |
Why?
|
| Cell Separation | 1 | 1987 | 199 | 0.020 |
Why?
|
| Ovum | 1 | 1987 | 61 | 0.020 |
Why?
|
| Neoplasms | 2 | 2001 | 3168 | 0.020 |
Why?
|
| Parity | 1 | 1987 | 95 | 0.020 |
Why?
|
| Steroids | 1 | 1987 | 166 | 0.020 |
Why?
|
| Peptides | 1 | 1990 | 653 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1989 | 916 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 67 | 0.010 |
Why?
|
| Inflammation | 1 | 1991 | 1049 | 0.010 |
Why?
|
| Pelvis | 1 | 1985 | 99 | 0.010 |
Why?
|
| Prognosis | 1 | 1993 | 3890 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1987 | 291 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1991 | 1447 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1987 | 883 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 655 | 0.010 |
Why?
|
| Sex Factors | 1 | 1987 | 1102 | 0.010 |
Why?
|
| Pregnancy, Ectopic | 1 | 1983 | 37 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 1990 | 752 | 0.010 |
Why?
|
| Aged | 3 | 2006 | 20395 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2006 | 1727 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 83 | 0.010 |
Why?
|
| Nitrites | 1 | 2002 | 34 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 89 | 0.010 |
Why?
|
| Nitrates | 1 | 2002 | 34 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2002 | 187 | 0.010 |
Why?
|
| Adenosarcoma | 1 | 2001 | 4 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1987 | 2427 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1982 | 359 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2001 | 50 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2001 | 61 | 0.010 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2001 | 68 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 300 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 1910 | 0.010 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2001 | 58 | 0.010 |
Why?
|
| Neutrophils | 1 | 1981 | 324 | 0.010 |
Why?
|
| Cell Movement | 1 | 1983 | 804 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1981 | 453 | 0.010 |
Why?
|
| Danazol | 1 | 1978 | 2 | 0.010 |
Why?
|
| Pseudopregnancy | 1 | 1978 | 4 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1978 | 25 | 0.010 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 1978 | 6 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1978 | 116 | 0.010 |
Why?
|
| Complement System Proteins | 2 | 1991 | 86 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 2458 | 0.010 |
Why?
|
| Random Allocation | 2 | 1990 | 308 | 0.010 |
Why?
|
| Keratins | 1 | 1995 | 62 | 0.010 |
Why?
|
| Synovial Membrane | 1 | 1995 | 31 | 0.010 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 1995 | 19 | 0.010 |
Why?
|
| Vimentin | 1 | 1995 | 47 | 0.010 |
Why?
|
| Isoflavones | 1 | 1995 | 13 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 1995 | 170 | 0.010 |
Why?
|
| Agglutination Tests | 2 | 1985 | 11 | 0.010 |
Why?
|
| Cell Division | 1 | 1995 | 689 | 0.010 |
Why?
|
| United States | 1 | 2006 | 7581 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 1985 | 465 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 1989 | 1385 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1995 | 752 | 0.010 |
Why?
|
| Diet | 1 | 1995 | 461 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1991 | 14 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 306 | 0.010 |
Why?
|
| Genital Diseases, Female | 1 | 1990 | 21 | 0.000 |
Why?
|
| DDT | 1 | 1990 | 4 | 0.000 |
Why?
|
| Cytological Techniques | 1 | 1990 | 30 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1989 | 54 | 0.000 |
Why?
|
| Safety | 1 | 1990 | 132 | 0.000 |
Why?
|
| Kinetics | 1 | 1991 | 1463 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1988 | 109 | 0.000 |
Why?
|
| Blood Coagulation Factors | 1 | 1988 | 20 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1989 | 291 | 0.000 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1988 | 28 | 0.000 |
Why?
|
| Electrophoresis | 1 | 1988 | 45 | 0.000 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 121 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1988 | 121 | 0.000 |
Why?
|
| Endopeptidases | 1 | 1988 | 114 | 0.000 |
Why?
|
| Myometrium | 1 | 1988 | 55 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1988 | 155 | 0.000 |
Why?
|
| Androstenedione | 1 | 1987 | 24 | 0.000 |
Why?
|
| Dihydrotestosterone | 1 | 1987 | 28 | 0.000 |
Why?
|
| Adnexal Diseases | 1 | 1987 | 22 | 0.000 |
Why?
|
| Gonadotropins | 1 | 1987 | 32 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1988 | 981 | 0.000 |
Why?
|
| Age Factors | 1 | 1990 | 1898 | 0.000 |
Why?
|
| Isotonic Solutions | 1 | 1984 | 17 | 0.000 |
Why?
|
| Sperm Agglutination | 1 | 1984 | 1 | 0.000 |
Why?
|
| Binding Sites, Antibody | 1 | 1984 | 47 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1984 | 315 | 0.000 |
Why?
|
| Risk | 1 | 1984 | 651 | 0.000 |
Why?
|
| Clinical Competence | 1 | 1987 | 810 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1984 | 1719 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1990 | 3155 | 0.000 |
Why?
|